Previous Article | Next Article ![]()
Infection and Immunity, September 1998, p. 4564-4567, Vol. 66, No. 9
Division of Infectious Diseases,
Received 12 January 1998/Returned for modification 13 March
1998/Accepted 8 June 1998
Interleukin-6-deficient (IL-6 In our model of murine
Chlamydia trachomatis pneumonia due to mouse pneumonitis
agent (MoPn), significant amounts of interleukin-6 (IL-6) are produced
in the lung in response to infection (10). The role of this
cytokine in this infection is unclear. IL-6 is known to play a critical
role in the differentiation of B cells into antibody-producing plasma
cells (1, 19). Plasma cells are a prominent component of the
host response to chlamydial infection, may be a histologic marker for
IL-6 production in this infection, and tend to correlate with
resistance to MoPn (4). This is consistent with the concept
that IL-6 and its immunologic effects may be important in host
resistance to chlamydia. To investigate this, we have employed
IL-6-deficient IL-6 The MoPn biovar of C. trachomatis was maintained in HeLa
cell culture and was Renografin density purified (24). The
HeLa cell material without MoPn contained less than 0.1 ng of endotoxin per ml by Limulus assay. MoPn was harvested and frozen at Table 1 shows the results of four
separate experiments in which B6129F2/J and
IL-6 To determine if the increased susceptibility of IL-6
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
A Role for Interleukin-6 in Host Defense against
Murine Chlamydia trachomatis Infection
![]()
ABSTRACT
Top
Abstract
Text
References
/
) knockout mice had
significantly increased Chlamydia trachomatis levels in
lung tissue and increased mortality compared to B6129F2/J
controls early after intranasal infection. Gamma interferon production
and chlamydia-specific antibody levels were consistent with a decreased
but reversible Th1-like response in IL-6
/
mice. IL-6 is
needed for an optimal early host response to this infection.
![]()
TEXT
Top
Abstract
Text
References
/
mice. It is known that
IL-6
/
mice are deficient in a variety of immunologic
functions, including Th1 antibody production, cytotoxic lymphocyte
function, very early neutrophil production, and Th1 cytokine production
(correctable by neutralization of IL-10) (6, 9, 16). These
defects make IL-6
/
mice more susceptible than controls
to a variety of pathogens (6, 9, 16, 21). The same host
defense mechanisms that are deficient in IL-6
/
mice are
also of known or potential importance with MoPn (2, 3, 7, 8, 17,
22, 24). Of particular interest, it is known that a Th1 host
response is important for successful resistance to MoPn and that a
Th2-biased response, including overproduction of IL-10 by a mouse
strain, can increase susceptibility (8, 29).
70°C until use. Mice at 6 to 8 weeks of age were infected in groups of five
each intranasally following sodium pentobarbital anesthesia with 1 × 102 to 5 × 103 inclusion-forming units
(IFU) of MoPn diluted in McCoy's modified 5A medium in a volume of
0.05 ml. The IL-6
/
mice employed in these studies had a
disruption in the second exon (first coding exon) of the IL-6 gene by
insertion of a Neor cassette (9). The genetic
background is mixed 129J×C57BL/6 and is not homogeneous. Controls are
B6129F2/J mice. The MoPn susceptibilities of the parental
strains (C57BL/6J and 129/J) are similar (13). All mice were
obtained from Jackson Laboratories (Bar Harbor, Maine). Quantitative
culture of infected lung tissue was performed with McCoy cell
monolayers and is reported as IFU per lung as in our previous studies
(28). MoPn antigen levels were determined by enzyme-linked
immunosorbent assay (ELISA) detection of chlamydial lipopolysaccharide
(Ortho Diagnostics, Inc., Raritan, N.J.) as in our previous
publications (11, 26). Assays of minced and filtered whole
lung material for gamma interferon (IFN-
) were performed by ELISA as
in our previous studies (24). The ELISAs for IL-6 and IL-10
(Genzyme, Cambridge, Mass.) were performed with the same material by
commercial ELISA according to the manufacturer's instructions. Plasma
samples were collected at the times specified below, and specific MoPn
antibody was determined by ELISA as previously described
(24). Rat monoclonal antibody to murine IL-10 (2A5) was
purchased from Genzyme (Cambridge, Mass.). Mice were given 200 µg
intravenously every other day, starting on day 0 of infection with
MoPn. Comparison of groups was performed by Mann-Whitney test with
significance reported as two tailed. For multiple comparisons, the
Mann-Whitney test was performed after analysis by nonparametric analysis of variance, with the alpha level adjusted for the number of
comparisons.
/
mice were infected with 1 × 102
(experiments 1 to 3) or 3 × 102 (experiment 4) IFU of
MoPn intranasally. Groups contained five mice each. Statistical
analysis was by Mann-Whitney test. In experiment 1, MoPn antigen levels
were determined in lung on day 5 postinfection. Mice were given either
rat antibody to IL-10 or control rat normal immunoglobulin (Ig). In
this experiment, a P value of <0.01 was considered
significant. IL-6
/
mice given normal rat Ig were
significantly more susceptible than B6129F2/J mice given
the same Ig (P < 0.008). Treatment with antibody to
IL-10 significantly reduced the susceptibility of IL-6
/
mice compared to that of IL-6
/
control mice
(P < 0.008). The same antibody treatment also tended to make B6129F2/J more resistant, but this was to a lesser
degree and did not reach statistical significance (P < 0.08). Because the B6129F2/J mice are not homogeneous, a
parental C57BL/6J group was also included and was not statistically
different from the B6129F2/J mice. Experiment 2 shows a
repeat experiment performed with only B6129F2/J and
IL-6
/
mice infected with the same MoPn dosage but not
given Ig. Quantitative cultures were performed on lung at day 5 in
IL-6
/
and B6129F2/J mice and were
consistent with the increased susceptibility of IL-6
/
mice seen in the prior experiment (P < 0.05 is
significant). In a similar experiment performed at day 15 (experiment
3), P < 0.017 was considered significant. By ELISA,
IL-6
/
mice were again significantly more susceptible
than controls to MoPn (P < 0.004), and treatment with
antibody to IL-10 reversed the increased susceptibility. Quantitative
culture data followed the same pattern as the antigen data but did not
reach statistical significance. An additional control group was
examined in which five B6129F2/J mice were given normal rat
IgG. This group did not differ significantly from the control group not
given IgG, and the two could be combined for statistical purposes. A
repeat experiment on day 15 is shown in experiment 4. Antigen levels were significantly elevated in IL-6
/
mice compared to
those in controls (P < 0.008 [P < 0.05 is significant]). MoPn antigen determinations were also performed
at day 32 in groups of six mice each infected with 102 IFU
of MoPn. The infection had resolved in both mouse groups at that time
with antigen levels of less than 50 ng/lung (not shown in Table 1).
Finally, two mortality experiments were performed, each with groups of
five mice at a MoPn dose of 5 × 103 IFU in which
mortality was monitored for 20 days. The data are combined. For
IL-6
/
mice, single mice died on days 7, 9, 10, 16, 17, and 18 and two mice each died on days 8 and 13, while
B6129F2/J mice died on days 9, 10, 13, 14, 15, and 18, with
four survivors (P = 0.036 [P < 0.05 is significant]).
TABLE 1.
Determination of MoPn levels in lung by ELISA or
culture at days 5 and 15 after infection
/
mice correlated with a shift toward a Th2 response in the
IL-6
/
animals reversible by antibody to IL-10, relevant
cytokine levels were measured in lung tissue on days 5 and 15 with five
mice per group (Table 2). A significant
decrease in IFN-
levels was observed in IL-6
/
mice
at days 5 and 15 (P < 0.015 [P < 0.017 is significant]). The decrease in IFN-
was corrected by
treatment with anti-IL-10 antibody. IL-6 levels were significantly
reduced at both days. No significant changes were observed in tumor
necrosis factor alpha (TNF-
) levels. Paradoxically, significant
differences were also not observed in IL-10 on the days examined, but
we did not examine very early periods.
TABLE 2.
Cytokine determinations in lung on days 5 and 15 after infection
Antibody levels to MoPn were also measured for IL-6
/
mice and controls at day 15 postinfection. The IgG response in
B6129F2/J mice was largely directed toward a Th1-like
response, with mean IgG1 levels of 14 ± 1 and IgG2a levels of
2,163 ± 1. IL-6
/
mice had a mixed Th1-Th2
pattern, with mean IgG1 levels of 321 ± 3 and IgG2a levels of
527 ± 2. These IgG1 levels were significantly different from
those in the B6129F2/J mice. Treatment with antibody to
IL-10 led to a return to a Th1-like response, with mean IgG1 levels of
17 ± 2 and IgG2a levels of 643 ± 2. The groups had 5 to 13 mice each. A repeat experiment showed similar results (not shown).
The data presented here are consistent with a beneficial role for IL-6
in host defense against C. trachomatis in our model of MoPn
pneumonia. The most likely mechanism involved is a role in initiating
or maintaining a Th1 response similar to that which has previously been
observed with Candida albicans (16). It is well
recognized that a Th1 response is necessary for optimal host defense
against MoPn (8, 23, 24, 29). IFN-
, TNF-
, and IL-12
are all involved (8, 12, 23, 26) in Th1-mediated host
defense against MoPn in vivo. Host defense mechanisms may also be
IFN-
independent (5, 12, 24) and may be analogous to that
involving IL-12 and TNF-
recently described for leishmaniasis (20, 24). TNF-
and IL-6 have multiple immunologic
interactions (discussed in references 1, 15, and
26) which may be of importance in this regard. In addition, IL-1a
(produced in our model in vivo [10]) has been shown to
play a pivotal role in the induction of the other proinflammatory
cytokines, including IL-6 in chlamydia-infected epithelial cells in in
vitro studies (15). While the antibody defect of
IL-6
/
mice with an increased tendency toward a Th2-like
response is also of interest regarding host defense, current data
indicate that cell-mediated immunity is probably more important than
humoral immunity in primary infection with MoPn (14, 18,
25). The fact that IL-6 is needed for optimal host defense
is consistent with the histological findings in our model, in
which plasma cells (a probable marker for the presence of IL-6) were
part of the successful host defense in the resistant (compared to
athymic) immunologically intact BALB/c background mouse but were absent in the host response of the very susceptible athymic mouse on the same
background (4, 28).
Additional data regarding cytokine abnormalities have recently been
reported for the IL-6
/
mouse during a much more acute
pulmonary infection with Streptococcus pneumoniae
(21). IL-10 levels were significantly elevated compared to
those in controls at 40 h after infection in that model, at which
time IFN-
levels tended to be decreased, consistent with a decreased
Th1 response in IL-6
/
mice at some periods in that
infection as well. With nonimmunocompromised mice, Yang et al. have
previously shown that treatment with anti IL-10 can make
susceptible mouse strains more resistant to MoPn, consistent with a
switch to a more Th1-directed immune response (29).
It is not clear what additional IL-6-dependent immunologic modalities,
if any, might be important in host defense against MoPn. Thus, some
aspects of the innate immune response to chlamydia (discussed in
reference 15) could be affected as well and could be
partly responsible for the increased susceptibility of the IL-6
/
animals. We have not fully evaluated the
possibility that a relative lack of neutrophils could play a role in
the observations noted in our study. Blood neutrophil counts performed
on day 5 were not clearly different in the two mouse groups
(unpublished data), but we did not investigate earlier periods.
Neutrophils are known to play a role in early host defense against MoPn
(2). We also did not investigate cytotoxic function in the
IL-6
/
animals and controls. It is known that NK cell
function is stimulated in lung early in infection in our model
(27) and thus could be involved in the cytotoxic host defect
known to be present in IL-6
/
mice. In this regard, it
is of note that preliminary studies in our laboratory have shown that
perforin-deficient mice are more susceptible to MoPn than controls
(unpublished data).
While these data were under review, Perry et al. published the results
of work with the genital model of MoPn infection showing that MoPn
infection was resolved in IL-6
/
mice, which is
consistent with what was seen in our study (13). While
IFN-
induced by MoPn antigen from spleen from infected IL-6
/
mice was reduced in their model, elevations in
MoPn early in infection did not reach statistical significance.
Therefore, the effect of IL-6
/
deficiency is apparently
greater in lung than in the genital tract. We would agree, however,
that IL-6 does not play the critical role in host defense against MoPn
equivalent to CD4+ T cells without which the infection does
not resolve (8, 28).
In summary, these data show that a deficiency of IL-6 in our model
leads to a diminished Th1-like response to chlamydial infection with
diminished IFN-
production and increased susceptibility. Thus, IL-6
can play a significant role in early host defense against C. trachomatis.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by the General Medical Research Service of the Veterans Administration.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Division of Infectious Diseases, Audie L. Murphy Memorial Veterans Hospital, 7400 Merton Minter Blvd., San Antonio, TX 78284. Phone: (210) 617-5109. Fax: (210) 949-3303. E-mail: dwight.williams{at}med.
Editor: J. R. McGhee
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Akira, S., T. Taga, and T. Kishimoto. 1993. Interleukin 6 in biology and medicine. Adv. Immunol. 54:1-78[Medline]. |
| 2. | Barteneva, N., I. Theodor, E. M. Peterson, and L. M. de la Maza. 1996. Role of neutrophils in controlling early stages of a Chlamydia trachomatis infection. Infect. Immun. 64:4830-4833[Abstract]. |
| 3. | Beatty, P. R., and R. S. Stephens. 1994. CD8+ T lymphocyte-mediated lysis of Chlamydia-infected L cells using an endogenous antigen pathway. J. Immunol. 153:4588-4595[Abstract]. |
| 4. | Coalson, J. J., V. T. Winter, L. B. Bass, J. Schachter, B. Grubbs, and D. M. Williams. 1987. Chlamydia trachomatis pneumonia in the athymic and normal BALB/c mouse. Br. J. Exp. Pathol. 68:399-412[Medline]. |
| 5. | Cotter, T. W., K. H. Ramsey, G. S. Miranpuri, C. E. Poulsen, and G. I. Byrne. 1997. Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice. Infect. Immun. 65:2145-2152[Abstract]. |
| 6. | Dalrymple, S. A., R. Slattery, D. M. Aud, M. Krishna, L. A. Lucian, and R. Murray. 1996. Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect. Immun. 64:3231-3235[Abstract]. |
| 7. |
Igietseme, J. U.,
D. M. Magee,
D. M. Williams, and R. G. Rank.
1994.
A role for CD8+ T cells in antichlamydial immunity defined by chlamydia-specific T-lymphocyte clones.
Infect. Immun.
62:5195-5197 |
| 8. | Igietseme, J. U., K. H. Ramsey, D. M. Magee, D. M. Williams, S. A. Theus, T. J. Kincy, and R. G. Rank. 1993. Resolution of murine chlamydial genital infection by the adoptive transfer of a CD4+, Th1 lymphocyte clone. Reg. Immunol. 5:317-324[Medline]. |
| 9. | Kopf, M., H. Baumann, G. Freer, M. Freudenberg, M. Lamers, T. Kishimoto, R. Zinkernagel, H. Bluethmann, and G. Kohler. 1994. Impaired immune and acute phase response in interleukin-6-deficient mice. Nature 368:339-342[Medline]. |
| 10. |
Magee, D. M.,
J. G. Smith,
C. A. Bleicker,
C. J. Carter,
L. F. Bonewald,
J. Schachter, and D. M. Williams.
1992.
Chlamydia trachomatis pneumonia induces the in vivo production of interleukin-1 and -6.
Infect. Immun.
60:1217-1220 |
| 11. | Magee, D. M., D. M. Williams, J. G. Smith, C. A. Bleicker, B. G. Grubbs, J. Schachter, and R. G. Rank. 1995. Role of CD8 T cells in primary chlamydia infection. Infect. Immun. 63:516-521[Abstract]. |
| 12. | Perry, L. L., K. Feilzer, and H. D. Caldwell. 1997. Immunity to Chlamydia trachomatis is mediated by T helper1 cells through IFN-gamma-dependent and -independent pathways. J. Immunol. 158:3344-3352[Abstract]. |
| 13. |
Perry, L. L.,
K. Feilzer, and H. D. Caldwell.
1998.
Neither interleukin-6 nor inducible nitric oxide synthase is required for clearance of Chlamydia trachomatis from the murine genital tract epithelium.
Infect. Immun.
66:1265-1269 |
| 14. |
Ramsey, K. H.,
L. S. F. Soderberg, and R. G. Rank.
1988.
Resolution of chlamydial genital infection in B-cell-deficient mice and immunity to reinfection.
Infect. Immun.
56:1320-1325 |
| 15. | Rasmussen, S. J., L. Eckmann, A. J. Quayle, L. Shen, Y.-X. Zhang, D. J. Anderson, J. Fierer, R. S. Stephens, and M. J. Kagnoff. 1997. Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J. Clin. Investig. 99:77-87[Medline]. |
| 16. |
Romani, L.,
A. Mencacci,
E. Cenci,
R. Spaccapelo,
C. Toniatta,
P. Puccetti,
F. Bistoni, and V. Poli.
1996.
Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice.
J. Exp. Med.
183:1345-1355 |
| 17. | Starnbach, M. N., M. J. Bevan, and M. F. Lampe. 1994. Protective cytotoxic T lymphocytes are induced during murine infection with Chlamydia trachomatis. 1994. J. Immunol. 153:5183-5189[Abstract]. |
| 18. | Su, H., K. Feilzer, H. D. Caldwell, and R. P. Morrison. 1997. Chlamydia trachomatis genital tract infection of antibody-deficient gene knockout mice. Infect. Immun. 65:1993-1999[Abstract]. |
| 19. |
Suematsu, S.,
T. Matsuda,
K. Aozasa,
S. Akira,
N. Nakano,
S. Ohno,
J. Miyazaki,
K. Yamamura,
T. Hirano, and T. Kishimoto.
1989.
IgG1 plasmacytosis in interleukin 6 transgenic mice.
Proc. Natl. Acad. Sci. USA
86:7547-7551 |
| 20. |
Taylor, A. P., and H. W. Murray.
1997.
Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene disrupted mice.
J. Exp. Med.
185:1231-1239 |
| 21. | van der Poll, T., C. V. Keogh, X. Guirao, W. A. Buurman, M. Kopf, and S. F. Lowrey. 1997. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J. Infect. Dis. 176:439-444[Medline]. |
| 22. | van Voorhis, W. C., L. K. Barrett, Y. T. Cosgrove Sweeney, C.-C. Kuo, and D. L. Patton. 1997. Repeated Chlamydia trachomatis infection of Macaca nemestrina fallopian tubes produces a Th1-like cytokine response associated with fibrosis and scarring. Infect. Immun. 65:2175-2182[Abstract]. |
| 23. |
Williams, D. M.,
G. I. Byrne,
B. Grubbs,
T. J. Marshall, and J. Schachter.
1988.
Role in vivo for gamma interferon in control of pneumonia caused by Chlamydia trachomatis in mice.
Infect. Immun.
56:3004-3006 |
| 24. | Williams, D. M., B. G. Grubbs, E. Pack, K. Kelly, and R. G. Rank. 1997. Humoral and cellular immunity in secondary infection due to murine Chlamydia trachomatis. Infect. Immun. 65:2876-2882[Abstract]. |
| 25. |
Williams, D. M.,
B. Grubbs, and J. Schachter.
1987.
Primary murine Chlamydia trachomatis pneumonia in B-cell-deficient mice.
Infect. Immun.
55:2387-2390 |
| 26. |
Williams, D. M.,
D. M. Magee,
L. F. Bonewald,
J. G. Smith,
C. A. Bleicker,
G. I. Byrne, and J. Schachter.
1990.
A role in vivo for tumor necrosis factor alpha in host defense against Chlamydia trachomatis.
Infect. Immun.
58:1572-1576 |
| 27. |
Williams, D. M.,
J. Schachter, and B. Grubbs.
1987.
Role of natural killer cells in infection with the mouse pneumonitis agent (murine Chlamydia trachomatis).
Infect. Immun.
55:223-226 |
| 28. | Williams, D. M., J. Schachter, D. J. Drutz, and C. V. Sumaya. 1981. Chlamydia trachomatis pneumonia in the immunocompromised (nude) mouse. J. Infect. Dis. 143:238-241[Medline]. |
| 29. | Yang, X., K. T. Hayglass, and R. C. Brunham. 1996. Genetically determined differences in IL-10 and IFN-gamma responses correlate with clearance of Chlamydia trachomatis mouse pneumonitis infection. J. Immunol. 156:4338-4344[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»